Quality Standards in State Programs Permitting Cannabis for Medical Uses

Area of Science:

• Pharmacology and Drug Regulation
• Public Health Policy

Background:

• Cannabis is federally illegal but state-level medical cannabis programs (MCPs) exist.
• Lack of standardized quality control in state MCPs poses risks.
• U.S. Food and Drug Administration (FDA) has not approved cannabis for medical use.

Purpose of the Study:

• To compare state regulations for medical cannabis quality with federal Current Good Manufacturing Practices (CGMPs).
• To identify gaps in quality standards for medical cannabis products.
• To advocate for improved quality control and standardized testing protocols.

Main Methods:

• Collected and reviewed state laws, regulations, and guidance documents for MCPs.
• Compared collected state regulations against federal CGMPs for finished drug products.
• Analyzed identified discrepancies in quality standards.

Main Results:

• Significant variability exists in state-level cannabis quality regulations.
• Many state regulations do not fully align with federal CGMP requirements.
• Gaps identified in manufacturing, processing, and packaging controls for medical cannabis.

Conclusions:

• Standardized quality guidelines, such as CGMPs, are needed for medical cannabis.
• Implementing consistent standards can enhance product quality and patient safety.
• Further research into standardized testing methodologies is crucial for the medical cannabis industry.